The U.S. Food and Drug Administration (FDA) is rethinking its decision to remove popular weight-loss and diabetes drugs from ...

Eli Lilly’s senior VP of information and R&D IT, Ramesh Durvasula, said Lilly will use AI and tech to transform the company.

Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.

There's no playbook for how to be competitive in artificial intelligence (AI) as a big pharma company, but Eli Lilly (NYSE: LLY) is taking a shot at developing one. With the appointment of a new chief ...

The U.K. will study whether Lilly's weight loss drug can get people back to work and help tackle long-term sickness ...

Clea Shearer, star of the Netflix show “Get Organized with The Home Edit,” discussed her breast cancer journey after ...

Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies say this will limit patient access.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Eli Lilly (NYSE: LLY) sells treatments for a wide variety of therapeutic areas, but one portfolio in particular has driven ...

In an assessment of 9 clinics and 166 users spanning from nurses, medical assistants, and advanced practice clinicians to ...

Eli Lilly is expanding its innovation digs to Beijing, opening two research centers called the Eli Lilly China Medical ...

The FDA is weighing a decision that could stop compounding pharmacies from legally making cheaper versions of Mounjaro and ...